RealTime Dynamix: Rheumatoid Arthritis Q4 is the fourth installment of the 2016 report series focusing on current and anticipated future trends in the RA treatment landscape. The Q4 report contains constant trended content, including current and future patient share, barriers to growth, industry contact rates, awareness and familiarity with products in development and sources of information about development compounds. Alternative variable content in Q4 includes rheumatologist statement agreements, brand analysis, impact of biosimilars, payer influence on prescribing, and patient compliance. Major in-line brands covered include Actemra, Cimzia, Enbrel, Humira, Orencia, Remicade, Rituxan, Simponi, and Xeljanz. RA pipe-line agents in the analysis include Baricitinib, Sarilumab, Sirukumab, and the recently approved biosimilar, Inflectra.
About Spherix Global Insights
Spherix Global Insights is a business intelligence and market research company, specializing in renal, autoimmune, neurologic and rare disease markets. Our aim is to apply our commercial experience and unique relationships within core specialty markets to translate data into insight, enabling our clients to make smarter business decisions.